Trinity Biotech (TRIB) Competitors $1.57 +0.01 (+0.64%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.54 -0.03 (-1.59%) As of 08/22/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRIB vs. MNOV, RPTX, PYXS, ATRA, VNRX, CNTX, IRD, OTLK, CUE, and ZIVOShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include MediciNova (MNOV), Repare Therapeutics (RPTX), Pyxis Oncology (PYXS), Atara Biotherapeutics (ATRA), VolitionRx (VNRX), Context Therapeutics (CNTX), Opus Genetics (IRD), Oncobiologics (OTLK), Cue Biopharma (CUE), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Its Competitors MediciNova Repare Therapeutics Pyxis Oncology Atara Biotherapeutics VolitionRx Context Therapeutics Opus Genetics Oncobiologics Cue Biopharma ZIVO Bioscience Trinity Biotech (NASDAQ:TRIB) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Is TRIB or MNOV more profitable? MediciNova has a net margin of 0.00% compared to Trinity Biotech's net margin of -68.48%. Trinity Biotech's return on equity of 0.00% beat MediciNova's return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-68.48% N/A -32.33% MediciNova N/A -23.12%-21.85% Does the media refer more to TRIB or MNOV? In the previous week, Trinity Biotech had 3 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Trinity Biotech and 2 mentions for MediciNova. MediciNova's average media sentiment score of 1.34 beat Trinity Biotech's score of 0.51 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TRIB or MNOV? Trinity Biotech has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Do analysts rate TRIB or MNOV? MediciNova has a consensus price target of $7.00, suggesting a potential upside of 433.37%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals & insiders hold more shares of TRIB or MNOV? 79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 13.6% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, TRIB or MNOV? MediciNova has lower revenue, but higher earnings than Trinity Biotech. MediciNova is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$61.56M0.46-$31.79M-$2.93-0.54MediciNova$1MN/A-$11.04M-$0.25-5.25 SummaryMediciNova beats Trinity Biotech on 10 of the 16 factors compared between the two stocks. Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.16M$10.84B$5.76B$9.58BDividend YieldN/A1.87%4.41%4.10%P/E Ratio-0.5420.9031.1026.05Price / Sales0.4629.67433.22103.03Price / CashN/A24.5537.7358.48Price / Book-0.813.519.536.61Net Income-$31.79M$211.77M$3.26B$265.56M7 Day Performance-3.09%4.44%2.10%1.97%1 Month Performance115.04%8.85%2.81%-0.36%1 Year Performance-21.50%-9.03%30.56%19.03% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.4712 of 5 stars$1.57+0.6%N/A-29.6%$28.16M$61.56M-0.54480Upcoming EarningsGap DownMNOVMediciNova2.5814 of 5 stars$1.33-1.5%$7.00+426.3%+7.6%$66.21M$1M-5.7810Positive NewsRPTXRepare Therapeutics2.2499 of 5 stars$1.54+0.3%$4.50+192.2%-46.5%$65.84M$53.48M-0.60180PYXSPyxis Oncology2.3396 of 5 stars$1.04-1.9%$8.67+733.3%-63.3%$65.67M$16.15M-0.6560Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeATRAAtara Biotherapeutics4.6717 of 5 stars$10.32-5.8%$20.00+93.8%+73.3%$65.31M$128.94M-2.77330News CoveragePositive NewsInsider TradeAnalyst RevisionVNRXVolitionRx2.152 of 5 stars$0.63-2.6%$3.50+460.0%+12.5%$64.99M$1.31M-1.7480News CoverageAnalyst RevisionGap UpCNTXContext Therapeutics3.5796 of 5 stars$0.68-5.9%$5.25+675.3%-64.3%$64.57MN/A-1.887Short Interest ↓IRDOpus Genetics1.6304 of 5 stars$1.06-0.9%$7.33+591.8%N/A$63.84M$10.99M-0.5014OTLKOncobiologics2.1504 of 5 stars$1.96+3.2%$9.60+389.8%-62.6%$63.78MN/A-2.1520News CoverageAnalyst RevisionGap UpCUECue Biopharma2.6826 of 5 stars$0.83+0.0%$4.00+381.1%+1.3%$62.62M$9.29M-1.2460News CoverageZIVOZIVO Bioscience0.2702 of 5 stars$16.21+11.9%N/A+112.3%$61.87M$15.85K-3.3210News CoverageGap Up Related Companies and Tools Related Companies MediciNova Competitors Repare Therapeutics Competitors Pyxis Oncology Competitors Atara Biotherapeutics Competitors VolitionRx Competitors Context Therapeutics Competitors Opus Genetics Competitors Oncobiologics Competitors Cue Biopharma Competitors ZIVO Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRIB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access